Literature DB >> 15328159

Distinct homeostatic requirements of CD4+ and CD4- subsets of Valpha24-invariant natural killer T cells in humans.

Denis V Baev1, Xiao-Hui Peng, Liping Song, Jerry R Barnhart, Gay M Crooks, Kenneth I Weinberg, Leonid S Metelitsa.   

Abstract

CD1d-restricted Valpha24-invariant natural killer T cells (iNKTs) are important in immunoregulation. CD4(+) and CD4(-) iNKTs develop with similar frequencies in murine thymus and depend on interleukin-15 (IL-15) in periphery. However, homeostatic requirements of iNKTs have not been analyzed in humans. We evaluated thymic production, peripheral dynamics, and functional maturation of human iNKTs. CD4(+) subset comprises 90% of iNKTs in mature thymocytes and cord blood (CB) but only 40% in adult blood. Using T-cell receptor excision circle (TREC) analysis, we directly measured in vivo replicative history of CD4(+) and CD4(-) iNKT cells. Compared to CD4(+), CD4(-) iNKTs contain fewer TRECs, express higher levels of IL-2Rbeta, and proliferate with higher rate in response to IL-15. In contrast, CD4(+) cells express higher levels of IL-7Ralpha and better respond to IL-7. Neither thymic nor CB iNKTs are able to produce cytokines unless they are induced to proliferate. Therefore, unlike in the mouse, human CD4(+) iNKTs are mainly supported by thymic output and limited peripheral expansion, whereas CD4(-) cells undergo extensive peripheral expansion, and both subsets develop their functions in periphery. These findings reveal important differences in homeostatic requirements and functional maturation between murine and human iNKTs that are to be considered for clinical purposes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328159     DOI: 10.1182/blood-2004-04-1629

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

Review 1.  Invariant NKT Cells and Control of the Thymus Medulla.

Authors:  Andrea J White; Beth Lucas; William E Jenkinson; Graham Anderson
Journal:  J Immunol       Date:  2018-05-15       Impact factor: 5.422

Review 2.  The innate immune system and HIV pathogenesis.

Authors:  Karla A Eger; Derya Unutmaz
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

Review 3.  Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.

Authors:  Leonid S Metelitsa
Journal:  Clin Immunol       Date:  2010-11-20       Impact factor: 3.969

4.  Application of nine-color flow cytometry for detailed studies of the phenotypic complexity and functional heterogeneity of human lymphocyte subsets.

Authors:  Veronica D Gonzalez; Niklas K Björkström; Karl-Johan Malmberg; Markus Moll; Carlotta Kuylenstierna; Jakob Michaëlsson; Hans-Gustaf Ljunggren; Johan K Sandberg
Journal:  J Immunol Methods       Date:  2007-12-04       Impact factor: 2.303

5.  Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2.

Authors:  Markus Moll; Jennifer Snyder-Cappione; Gerald Spotts; Frederick M Hecht; Johan K Sandberg; Douglas F Nixon
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

Review 6.  Raising the NKT cell family.

Authors:  Dale I Godfrey; Sanda Stankovic; Alan G Baxter
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

7.  Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells.

Authors:  Xiangshu Wen; Ping Rao; Leandro J Carreño; Seil Kim; Agnieszka Lawrenczyk; Steven A Porcelli; Peter Cresswell; Weiming Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

8.  Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.

Authors:  Liping Song; Tasnim Ara; Hong-Wei Wu; Chan-Wook Woo; C Patrick Reynolds; Robert C Seeger; Yves A DeClerck; Carol J Thiele; Richard Sposto; Leonid S Metelitsa
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease.

Authors:  Abel Trujillo-Ocampo; Hyun-Woo Cho; Amanda C Herrmann; Wilfredo Ruiz-Vazquez; Andrew B Thornton; Hong He; Dan Li; Mariam A Qazilbash; Qing Ma; Steven A Porcelli; Elizabeth J Shpall; Jeffrey Molldrem; Jin S Im
Journal:  Cytotherapy       Date:  2018-07-31       Impact factor: 5.414

10.  EBV promotes human CD8 NKT cell development.

Authors:  Yuling He; Ruijing Xiao; Xiang Ji; Li Li; Lang Chen; Jie Xiong; Wei Xiao; Yujuan Wang; Lijun Zhang; Rui Zhou; Xinti Tan; Yongyi Bi; Yan-Ping Jiang; Youxin Jin; Jinquan Tan
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.